257 related articles for article (PubMed ID: 29714594)
1. A Comparative Review of Marketing Authorization Decisions in Switzerland, the EU, and the USA.
Dalla Torre Di Sanguinetto S; Heinonen E; Antonov J; Bolte C
Ther Innov Regul Sci; 2019 Jan; 53(1):86-94. PubMed ID: 29714594
[TBL] [Abstract][Full Text] [Related]
2. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
3. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
[TBL] [Abstract][Full Text] [Related]
4. A decade comparison of regulatory decision patterns for oncology products to all other non-oncology products among Swissmedic, European Medicines Agency, and US Food and Drug Administration.
Rohr UP; Iovino M; Rudofsky L; Li Q; Juritz S; Gircys A; Wildner O; Bujar M; Bolte C; Dalla Torre di Sanguinetto S; Wolfer A
Clin Transl Sci; 2023 Sep; 16(9):1569-1581. PubMed ID: 37408165
[TBL] [Abstract][Full Text] [Related]
5. A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU.
da Costa Gonçalves F; Demirci E; Zwiers A
Clin Transl Sci; 2022 Aug; 15(8):1959-1967. PubMed ID: 35561071
[TBL] [Abstract][Full Text] [Related]
6. Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study.
Xie J; Li J; Liu Y; Wang H; Wang Y; Yang Y; Chen Y; Jiang R; Shao R
BMJ Open; 2023 Jun; 13(6):e069132. PubMed ID: 37286329
[TBL] [Abstract][Full Text] [Related]
7. Effect of Project Orbis participation by the Swiss regulator on submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis.
Zosso-Pavic M; Li Q; Atiek E; Wolfer A; Rohr UP
Lancet Oncol; 2024 Jun; 25(6):770-778. PubMed ID: 38754450
[TBL] [Abstract][Full Text] [Related]
8. Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States.
Iglesias-Lopez C; Obach M; Vallano A; Agustí A
Cytotherapy; 2021 Mar; 23(3):261-274. PubMed ID: 33483292
[TBL] [Abstract][Full Text] [Related]
9. A Comparison of EMA and FDA Decisions for New Drug Marketing Applications 2014-2016: Concordance, Discordance, and Why.
Kashoki M; Hanaizi Z; Yordanova S; Veselý R; Bouygues C; Llinares J; Kweder SL
Clin Pharmacol Ther; 2020 Jan; 107(1):195-202. PubMed ID: 31306483
[TBL] [Abstract][Full Text] [Related]
10. An Analysis of Regulatory Timing and Outcomes for New Drug Applications Submitted to Swissmedic: Comparison With the US Food and Drug Administration and the European Medicines Agency.
Dörr P; Wadworth A; Wang T; McAuslane N; Liberti L
Ther Innov Regul Sci; 2016 Nov; 50(6):734-742. PubMed ID: 30231740
[TBL] [Abstract][Full Text] [Related]
11. Investigation assessing the publicly available evidence supporting postmarketing withdrawals, revocations and suspensions of marketing authorisations in the EU since 2012.
Lane S; Lynn E; Shakir S
BMJ Open; 2018 Jan; 8(1):e019759. PubMed ID: 29362275
[TBL] [Abstract][Full Text] [Related]
12. Real-World Data in the Postapproval Setting as Applied by the EMA and the US FDA.
Mofid S; Bolislis WR; Kühler TC
Clin Ther; 2022 Feb; 44(2):306-322. PubMed ID: 35074209
[TBL] [Abstract][Full Text] [Related]
13. Regulatory issues with multiplicity in drug approval: Principles and controversies in a changing landscape.
Benda N; Brandt A
J Biopharm Stat; 2018; 28(1):3-9. PubMed ID: 29065277
[TBL] [Abstract][Full Text] [Related]
14. EU decision-making for marketing authorization of advanced therapy medicinal products: a case study.
de Wilde S; Coppens DGM; Hoekman J; de Bruin ML; Leufkens HGM; Guchelaar HJ; Meij P
Drug Discov Today; 2018 Jul; 23(7):1328-1333. PubMed ID: 29574211
[TBL] [Abstract][Full Text] [Related]
15. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
Reeve LM
Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
[TBL] [Abstract][Full Text] [Related]
16. Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US.
Nagai S; Ozawa K
Br J Haematol; 2016 Jul; 174(2):249-54. PubMed ID: 27018163
[TBL] [Abstract][Full Text] [Related]
17. A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors.
Shah RR; Roberts SA; Shah DR
Br J Clin Pharmacol; 2013 Sep; 76(3):396-411. PubMed ID: 23362829
[TBL] [Abstract][Full Text] [Related]
18. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
Senderowicz AM; Pfaff O
Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
[TBL] [Abstract][Full Text] [Related]
19. Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999-2014.
Hatswell AJ; Baio G; Berlin JA; Irs A; Freemantle N
BMJ Open; 2016 Jun; 6(6):e011666. PubMed ID: 27363818
[TBL] [Abstract][Full Text] [Related]
20. Approval probabilities and regulatory review patterns for anticancer drugs in the European Union.
Hartmann M; Mayer-Nicolai C; Pfaff O
Crit Rev Oncol Hematol; 2013 Aug; 87(2):112-21. PubMed ID: 23433721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]